The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

NCT04542837 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

HCC

Interventions

BIOLOGICAL: KN046
DRUG: Lenvatinib

Sponsor

Peking University Cancer Hospital & Institute